<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00320008</url>
  </required_header>
  <id_info>
    <org_study_id>KA92071gm</org_study_id>
    <nct_id>NCT00320008</nct_id>
  </id_info>
  <brief_title>Intensified Multifactorial Intervention in Patients With Type 2 Diabetes and Microalbuminuria</brief_title>
  <acronym>Steno-2</acronym>
  <official_title>Intensified Multifactorial Intervention in Patients With Type 2 Diabetes and Microalbuminuria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peter Gæde</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Steno Diabetes Center Copenhagen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether intensified multifactorial intervention
      comprising both behaviour modification and polypharmacy can reduce the risk for late diabetic
      complications compared to standard treatment in patients with type 2 diabetes and
      microalbuminuria.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overall description of the Steno-2 Study is stated in four protocols approved by the
      regulatory authorities in Denmark. The protocol identification numbers are KA 92071gm (4
      years intervention ), KA-99035g (8 years intervention ), KA-99035-GS (13 years follow-up
      since intervention start) and H-KA-99035-GS (21 year follow-up since intervention start).

      The aim of the study was to determine whether intensified multifactorial intervention
      comprising both behaviour modification and polypharmacy can reduce the risk for late diabetic
      complications compared to standard treatment in patients with type 2 diabetes and
      microalbuminuria. The primary end point after four years of intervention was to progression
      to diabetic nephropathy with other microvascular complications as secondary end points. The
      primary end point after eight years of intervention was a composite CVD endpoint with
      microvascular complications as secondary end points.

      The interventional part of the study was ended in December 2001 after a total of eight years
      of intervention. From that time on, all patients were followed in a post-trial study. Also,
      during post-trial period all patients in both original treatment arms received similar
      treatment resembling the treatment given in the original intensive arm of the study. The aim
      of the post-trial follow-up was to investigate the effect of intensified multifactorial
      intervention on i) mortality and ii) years of life gained, respectively, with such an
      interventional approach.

      Endpoints in the two parts of the post-trial follow-up:

      Part one at 13 years since start of intervention:

      Primary endpoint: Total mortality. Secondary endpoints: Cardiovascular endpoints as defined
      previously; Microvascular disease.

      Part two at 21 years since start of intervention:

      Primary endpoint: Difference in median time to 50% mortality in each of the two original
      treatment groups Secondary endpoints: Cardiovascular endpoints as defined previously;
      Recurrent cardiovascular events; Microvascular disease.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 1992</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Actual">December 2001</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diabetic nephropathy</measure>
    <time_frame>Four years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Combined cardiovascular endpoint</measure>
    <time_frame>Eight years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total mortality</measure>
    <time_frame>13 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Years of life years gained</measure>
    <time_frame>21 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>22 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular disease mortality</measure>
    <time_frame>22 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>22 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>22 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coronary interventions</measure>
    <time_frame>22 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amputations</measure>
    <time_frame>22 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular surgery</measure>
    <time_frame>22 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diabetic retinopathy</measure>
    <time_frame>22 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diabetic nephropathy</measure>
    <time_frame>22 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diabetic neuropathy</measure>
    <time_frame>22 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Standard Treatment Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This arm will at any time during the active intervention period follow treatment guidelines by the Danish Medical Association for the treatment of type 2 diabetes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intensive Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm will during the active intervention period be treated according to intensified multiple risk factor intervention following strict guidelines set out by the study protocol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Diet</intervention_name>
    <arm_group_label>Intensive Treatment Arm</arm_group_label>
    <arm_group_label>Standard Treatment Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Exercise</intervention_name>
    <arm_group_label>Intensive Treatment Arm</arm_group_label>
    <arm_group_label>Standard Treatment Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Stop smoking</intervention_name>
    <arm_group_label>Intensive Treatment Arm</arm_group_label>
    <arm_group_label>Standard Treatment Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucose lowering therapy</intervention_name>
    <arm_group_label>Intensive Treatment Arm</arm_group_label>
    <arm_group_label>Standard Treatment Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Blood pressure lowering therapy</intervention_name>
    <arm_group_label>Intensive Treatment Arm</arm_group_label>
    <arm_group_label>Standard Treatment Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lipid lowering therapy</intervention_name>
    <arm_group_label>Intensive Treatment Arm</arm_group_label>
    <arm_group_label>Standard Treatment Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes

          -  Microalbuminuria

        Exclusion Criteria:

          -  Stimulated serum C-peptide concentration less than 600 pmol/L

          -  Pancreatic insufficiency or diabetes secondary to pancreatitis

          -  Alcohol abuse

          -  Non-diabetic kidney disease

          -  Life-threatening disease with death probable within 4 years of study start
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Gaede, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Slagelse Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Slagelse Hospital</name>
      <address>
        <city>Slagelse</city>
        <zip>4200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <results_reference>
    <citation>Gaede P, Vedel P, Parving HH, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet. 1999 Feb 20;353(9153):617-22.</citation>
    <PMID>10030326</PMID>
  </results_reference>
  <results_reference>
    <citation>Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003 Jan 30;348(5):383-93.</citation>
    <PMID>12556541</PMID>
  </results_reference>
  <results_reference>
    <citation>Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008 Feb 7;358(6):580-91. doi: 10.1056/NEJMoa0706245.</citation>
    <PMID>18256393</PMID>
  </results_reference>
  <results_reference>
    <citation>Gæde J, Oellgaard J, Ibsen R, Gæde P, Nørtoft E, Parving HH, Kjellberg J, Pedersen O. A cost analysis of intensified vs conventional multifactorial therapy in individuals with type 2 diabetes: a post hoc analysis of the Steno-2 study. Diabetologia. 2019 Jan;62(1):147-155. doi: 10.1007/s00125-018-4739-3. Epub 2018 Oct 6.</citation>
    <PMID>30293113</PMID>
  </results_reference>
  <results_reference>
    <citation>Oellgaard J, Gæde P, Persson F, Rossing P, Parving HH, Pedersen O. Application of urinary proteomics as possible risk predictor of renal and cardiovascular complications in patients with type 2-diabetes and microalbuminuria. J Diabetes Complications. 2018 Dec;32(12):1133-1140. doi: 10.1016/j.jdiacomp.2018.09.012. Epub 2018 Sep 24.</citation>
    <PMID>30282584</PMID>
  </results_reference>
  <results_reference>
    <citation>Kjaer LK, Oellgaard J, Henriksen T, Gaede P, Pedersen O, Poulsen HE. Indicator of RNA oxidation in urine for the prediction of mortality in patients with type 2 diabetes and microalbuminuria: A post-hoc analysis of the Steno-2 trial. Free Radic Biol Med. 2018 Dec;129:247-255. doi: 10.1016/j.freeradbiomed.2018.09.030. Epub 2018 Sep 21.</citation>
    <PMID>30244028</PMID>
  </results_reference>
  <results_reference>
    <citation>Oellgaard J, Gæde P, Rossing P, Persson F, Parving HH, Pedersen O. Intensified multifactorial intervention in type 2 diabetics with microalbuminuria leads to long-term renal benefits. Kidney Int. 2017 Apr;91(4):982-988. doi: 10.1016/j.kint.2016.11.023. Epub 2017 Feb 7. Erratum in: Kidney Int. 2017 May;91(5):1257.</citation>
    <PMID>28187983</PMID>
  </results_reference>
  <results_reference>
    <citation>Oellgaard J, Gæde P, Rossing P, Rørth R, Køber L, Parving HH, Pedersen O. Reduced risk of heart failure with intensified multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: 21 years of follow-up in the randomised Steno-2 study. Diabetologia. 2018 Aug;61(8):1724-1733. doi: 10.1007/s00125-018-4642-y. Epub 2018 May 30.</citation>
    <PMID>29850922</PMID>
  </results_reference>
  <results_reference>
    <citation>Gæde P, Oellgaard J, Carstensen B, Rossing P, Lund-Andersen H, Parving HH, Pedersen O. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia. 2016 Nov;59(11):2298-2307. doi: 10.1007/s00125-016-4065-6. Epub 2016 Aug 16.</citation>
    <PMID>27531506</PMID>
  </results_reference>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 27, 2006</study_first_submitted>
  <study_first_submitted_qc>April 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2006</study_first_posted>
  <last_update_submitted>April 2, 2019</last_update_submitted>
  <last_update_submitted_qc>April 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Steno Diabetes Center Copenhagen</investigator_affiliation>
    <investigator_full_name>Peter Gæde</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

